IBIO123

N/A

Report date: 2022/01/18 18:05:21

Base Information

Drug NameIBIO123
Drug Alias NameIBIO-123
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUkraineSouth Africa +[4] 
CombinationsYes
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmune Biosolutions Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmune Biosolutions Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A